!!!!!!

PetVivo!Holdings,!Inc.!!OTCPINK:!PETV!

!

October!1,!2015!

!!FORWARDELOOKING!STATEMENTS!Statements!in!this!presentaNon!that!are!not!historical!facts!are!“forwardElooking!statements”.!Viewers!are!cauNoned!that!any!such!statements!are!not!guarantees!of!future!performance!and!that! actual! developments!or! results!may! vary!materially! from!those! in! these! “forwardElooking! statements”.! Statements!regarding! future! plans! and! objecNves! are! forwardElooking!statements! that! involve! various! risks! and!uncertainNes.!Much!of! the! informaNon,! analysis,! plans! and! conclusions! contained!herein! were! assembled! or! derived! by! company!management!and! there! can!be!no! assurance! that! they!will! prove! accurate.!No! securiNes! regulator! or! stock! exchange! has! reviewed! or!accepted! responsibility! for! the! adequacy! or! accuracy! of! this!presentaNon.!

PetVivo!Holdings!(PETV)!

GelEDel!! PetVivo!•  Royalty!Free!Mayo!Clinic!Technology!Transfer!•  IniNal!Focus!–!Vet!Devices!Developed!for!Humans!•  No!FDA!Approval!Required!for!Vet!Devices!!•  Kush!Canine!ProducNon!&!Revenues!Q1!‘16!!•  Cash!Flow!PosiNve!Within!12!Months!PostElaunch!•  Validated!&!Scalable!Manufacturing!•  Successful!Pivotal!FDA!Human!Trial!!•  $13M+!Invested!Including!$7M!From!NIH!•  Strong!IP!&!Extensive!Product!Pipeline!

!Our!Pet/Vet!Market!U.S.!Pet!Owners!Spend*!!

Source:!APPA;!USD!in!Billions!*!Agricultural!and!professional!equine!markets!not!included!!!

•  Large!and!Growing!Market!o  2015E!U.S.!Pet!Spend!$60B!

•  InsensiNve!to!Recent!Recession!!•  68%!of!U.S.!Households!!!!

o  96M!Cats!o  83M!Dogs!o  8.3M!Horses!

•  Vet!Care!a!Leading!Growth!Driver!o  $15B!in!U.S.!(2014)!o  26%!of!Pet!Spend!o  FiveEyear!CAGR!of!6.4%!

•  Pet!TherapeuNcs!Account!for!Just!3%!of!All!Pet!Expenditures!!

•  Market!Ripe!for!Bener!and!More!EffecNve!TherapeuNcs!

$59!!$56!

$53!$51!

$48!$46!

$43!$41!

$39!$36!

$34!$32!

$30!$29!

$23!$21!

$17!

$0!!

$10!!

$20!!

$30!!

$40!!

$50!!

$60!!

Problem:!Canine!&!Equine!!Lameness!From!OsteoarthriNs!(OA)!•  No!current!treatment!for!OA,!only!palliaNve!pain!therapy!

or!joint!replacement!•  OA!is!a!condiNon!with!degeneraNng!carNlage,!creaNng!

joint!sNffness!from!mechanical!stress!resulNng!in!inflammaNon!&!pain!

•  OA!lameness!worsens!with!Nme!from!ongoing!loss!of!protecNve!cushion!and!lubricity!(i.e.,!loss!of!slippery!padding)!

•  NSAIDS!are!used!to!alleviate!the!pain!and!inflammaNon,!but!longEterm!cause!gastric!problems!

•  NSAIDS&do&not&treat&the&car0lage&degenera0on&issue&to&halt&or&slow&the&progression&of&the&OA&condi0on&&

Our!SoluNon:!Kush™!Joint!InjecNon!for!the!Treatment!of!OsteoarthriNs!

•  Superior!treatment!to!safely!improve!joint!funcNon!•  ReparaNve!Kush!parNcles!are!lubricious,!cushioning!&!longElasNng!•  These!spongy!proteinEbased!parNcles!mimic!the!composiNon!and!

protecNve!funcNon!of!carNlage!(i.e.,!providing!both!a!slippery!cushion!and!healing!scaffolding)!

•  Kush!parNcles!protect!the!joint!as!an!arNficial!carNlage!

Pain& Inflamma0on&

Kush&Treated&Joint&

Kush&Par0cles&Cushioning&and&Protec0ng&Joint&

4&layers&of&car0lage&

Painful&Inflamed&Joint&

!!!!Kush!Canine!OA!Treatment!•  Kush!Canine!ParNcles!Injected!!Into!Synovial!Space!!

•  Standard!IntraEArNcular!Technique!!•  No!Special!Training!•  MulNple!Joints!Can!Be!Treated!Simultaneously!

•  No!Recovery!Period!•  Case!Studies!Show!That!Kush!Canine!Increases!WalkingERunning!AcNvity!&!Eliminates!Pain!MedicaNons!(e.g.,!NSAIDS)!

!!!Kush!Equine!Lameness!Treatment!•  No!Current!ReparaNve!Treatment!for!Equine!Joint!Lameness!

•  Kush!Equine!Injected!Into!Synovial!Joint!Space!Using!Standard!Technique!

•  No!Special!Training!Required!•  MulNple!Joints!Can!Be!Treated!•  No!Special!PostETreatment!!•  Case!Studies!Demonstrate!the!!Reduced!Appearance!of!Lameness!Beyond!Six!Months!

Kush!!vs.!CompeNNon!Treatment( Rimadyl((NSAID) Hyaluronic(Acid(((((((((((((((((((((((((((((

Joint(InjectionsTotal(Joint(Replacement( Kush™(Canine(0(PetVivo

Pro Temporary(Pain(ReliefTemporary(Pain(Relief(((((((((((((((((Good(Safety(Profile (Joint(Replaced

Protects(Joint(0(Increases(

Activity(0(Reduces(Pain(0(

Excellent(Safety(Profile

Con

Potential(for(Gastric(Ulcers(and(Kidney(Problems(Does(

Not(Treat(Condition(

Effectiveness(Diminishes(Over(30(Days(J(

Minimally(Invasive(((((

Invasive(and(Expensive(Surgical(Procedure(

Requiring(RehabilitationMinimally(Invasive(((

Typical(((((

Owner(Cost*

$0.90(J($2.40(per(day(((((((Blood(Testing(Required((to(

Monitor(Toxicity$150(J($250(per(joint

$2,000(J($4,000((((((((((((((((per(joint $400(0($600(per(joint(

Annual(((((((

Owner(Cost($400(J($700 $1,800(J($3000 $2,000(J($4,000 $400(0($600(

Treatment(Once(or(Twice(Daily(((((((((((((((

by(OwnerMonthly((((((((((((((((((((((((((((

at(Vet((Clinic(Surgery(and(Rehab Typically(Once(per(Year(((((((((((((

at(Vet(Clinic

Vet(Revenue(

Opportunity

Vet(Revenue(Declining(Animal(Scripts(Can(Now(be(Filled(at(Most(Pharmacies

(Short(Duration(of(Effectiveness(Limits(Repeat(Business

Good(OneJTime(Revenue(Surgical(Expertise(Required(((((

Price(Resistance(

Repeat/Referral(Business(

Due(to(Kush's(Effectiveness/(

Duration/Value(Multiple(

Joints(Can(Be(Treated

*Costs(may(very(depending(on(animal(size,(dosing(and(treatment(location

IniNal!Kush!Markets!&!Comps!•  Kush!Canine:!OsteoarthriNs!Market!EsNmate!!!

•  20,000,000!dogs!with!OsteoarthriNs!(USEEU)!•  $2.6B&USIEU&Market&&

•  Kush!Equine:!Lameness!Market!EsNmate!•  1,000,000!lame!horses!(USEEU)!•  $600M&USIEU&Market&

•  Our!comp!group!consists!of!companion!animal!diagnosNc/pharm!companies!Abaxis,!Aratana!TherapeuNcs,!IDEXX!and!ZoeNs.!Abaxis,!IDEXX!and!ZoeNs!currently!trade!at!4.0x!to!5.0x!2014!sales.!!

Pet!Business!Model:!PetVivo,!Inc.!•  US!DistribuNon!!

o  Sales!through!exisNng!veterinary!distributors!!•  MWI,!Panerson!Veterinary,!Butler!Schein!Animal!Health!!

o  Regional!Business!Development!&!Training!Reps!•  Educate!veterinarians!&!clinic!Staff!•  Provide!distributor!rep!training!•  Technical!support!

o  MarkeNng!&!Training!•  Demand!side!pull!strategy!E!costEeffecNve!social!media!!•  Online!Media!E!consumer!educaNon!&!veterinary!professional!training!

•  Canadian!DistribuNon!!o  Establish!Canadian!distribuNon!&!technical!support!&!training!

•  European!DistribuNon!o  Establish!regional!EU!distribuNon!channels!!

!! !Pet&Therapeu0cs&& Species! Safety! Pilot!! Efficacy! Commercial!!VDE01! &Osteoarthri0s& !Canine!(Kush)! !! !! !! !! Q1&2016&&VDE02!!&Osteoarthri0s& !Equine!(Kush)! !! !! !! !! Q3&2016&VDE03!!&Digital&Cushion&Lameness& !Equine!&!Bovine! !! !! !! 2016&VDE04! &Urinary&Incon0nence&& !Canine! !! !! !! !! 2017&VDE06! &Osteoarthri0s& !Feline!(Kush)! !! !! !! !! 2017&

Pet!&!Human!Product!Pipeline!

Par0cle&Based&Devices&& Molded&Vascular&Devices&& Drug&Delivery&Devices&

!!!Human&Therapeu0cs& Biomaterial!

Safety!Proof!of!Concept!

Preclinical!Studies!

Pivotal!!Trial!!

FDA!Submission! Launch!

HDE05! &Dermal&Filler& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2017&HDE07! &Osteoarthri0s& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2017&HDE08! &Dermal&Filler&I&Lip& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2018&HDE09! &Spinal&Disc&Repair& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2018&HDE10! &Arteriovenous&(AV)&Shunt&& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2018&HDE11! &Limb&Salvage&Shunt& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2018&HDE12! &Female&Urinary&Incon0nence& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2019&HDE13! &Peripheral&Vascular&Gra^&& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2019&HDE14! &Coronary&Artery&Bypass&Gra^& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2019&HDE15! &Drug&Elu0ng&Stent&Coa0ng& !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2019&HDE16! &Mucoadhesive&Fentanyl&& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2019&HDE17! &Vasculitus&Wound&Closure& !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! !! 2019&

&

9,107,937&–!Wound!Treatments!with!Crosslinked!Protein!Amorphous!Biomaterials!8,871,267&–!Protein!Matrix!Materials,!Devices!and!Methods!of!Making!and!Using!Thereof!!8,623,393&–!Biomatrix!Structural!Containment!and!FixaNon!Systems!and!Methods!of!Use!Thereof!!8,529,939&–!Mucoadhesive!Drug!Delivery!Devices!and!Methods!of!Making!and!Using!Thereof!!8,465,537!–!Encapsulated!or!Coated!Stent!Systems!8,153,591!–!Protein!Biomaterials!and!Biocoacervates!and!Methods!of!Making!and!Using!Thereof!7,662,409!–!Protein!Matrix!Materials,!Devices!and!Methods!of!Making!and!Using!Thereof!!6,342,250!–!Drug!Delivery!Devices!Comprising!BioEdegradable!Protein!for!the!Controlled!Release!of!Pharmacologically!AcNve!Agents!&!Method!of!Making!12&Foreign&Patents&Granted&&&Allowed&!16&Patent&Apps&Pending&(US&&&Foreign)!&&

Comprehensive!IP!Porvolio!!!!!!!!!!!!!!!Eight!Issued!US!Patents!

VerNcally!Integrated!IP!Porvolio!Raw!Materials!to!Finished!Products!•  Eight!US!Patents!with!328!Claims!•  Broad!Claim!Language!E!“Comprising”!TransiNons!•  Our!Patents!&!Trade!Secrets!Protect:!

•  Protein!&!Carbohydrate!Based!ThermoplasNcs!•  Biomaterials!of!Many!ComposiNons!!•  Medical,!Drug!Delivery!&!CombinaNon!Products!•  Medical!&!PharmaceuNcal!ApplicaNons!•  Validated!SelfEAssembly!ProducNon!Processes!

•  Our!Intellectual!Property!is!Extensively!Cited!!•  Over!150!Patent!Examiners!CitaNons!!•  Over!250!Patent!Applicant!CitaNons!

•  The!biomaterial!in!Kush!is!made!up!of!an!aggregated!assembly!of!nanoEsized!spheres!(i.e.!Proteoids)!

•  Each!Proteoid!is!composed!of!proteins!and!carbohydrates,!the!building!blocks!of!mammalian!Nssue!

Proprietary!AggregaNon!/!SelfEAssembly!Manufacturing!Process!

Experienced!Proven!Leadership&

Randall&A.&Meyer&Chief!OperaNng!Officer!&!Director.!Mr.!Meyer!has!over!25!years!of!leadership!experience!in!medical!device!development!and!commercializaNon!including!experNse!in!successfully!growing!medical!device!companies!from!concept!to!profitability!as!a!Chief!ExecuNve!Officer,!Chief!OperaNng!Officer!and!Director.&!!!

John&Lai&CoEfounder,!CEO!&!Chairman.!Mr.!Lai!has!over!30!years!of!senior!operaNons!and!financial!experience!and!has!served!as!CEO,!President,!CFO,!and!Director!for!several!public!companies.!Mr.!Lai!has!extensive!experience!in!capital!structure,!financial!analysis,!business!formaNon,!mergers,!acquisiNons!and!driving!producNon!revenue!growth.!!

John&F.&Dolan&CoEfounder,!CFO,!General!Counsel!&!Director.!Mr.!Dolan!has!over!25!years!of!experience!as!a!legal!professional,!patent!anorney,!corporate!council!and!senior!execuNve!as!an!expert!in!the!uNlizaNon!of!IP!to!capitalize!and!commercialize!enNNes.!He!has!served!as!a!USPTO!patent!examiner!in!the!organic!chemistry!and!biotechnology!area.!!

David&B.&Masters,&Ph.D.&President,!CTO!&!Director.!Dr.!Masters!is!an!entrepreneur,!biochemist,!biomaterials!expert!and!inventor!with!credenENals!from!Rutgers,!Harvard,!U!of!MN!and!the!Mayo!Clinic.!Dr.!Masters!has!over!30!years!of!experience,!including!>50!publicaNons,!FDA!clinical!trial,!36!issued!or!pending!patents!and!>$7!million!in!NIH!grant!awards.!!

Proven!Products!E!Validated!Mfg.!!Pet!Market!Launch!Ready!

•  Demonstrated!Human!Safety!&!Efficacy!o  Classified!as!a!Medical!Device!by!the!FDA!!o  Pivotal!FDA!Human!Trial!Successfully!Completed!!o  Ten!Years!of!Safety!&!Efficacy!in!Many!Species!

•  Validated!Manufacturing!!o  Manufacturing!FDA!Validated!For!Human!Trial!!o  SingleEUse!Inline!MFG!Processes!o  Very!Scalable!Manufacturing!!o  Low!CAPEX!Infrastructure!!o  Room!Temp!Stable!Beyond!24!Months!

•  Commercial!Ready!in!Pet/Vet!Market!o  ParNcles!Defined!as!a!Medical!Device!!o  No!FDA!Clearance!Required!for!Vet!Devices!o  Significant!Margins!!!!!

!

!!

CloseEup!of!syringe!needle!

point!

ParNcles!

PetVivo!Investment!Highlights!•  IniNal!Kush!product!producNon!&!revenues!Q1!2016!•  Cash!flow!posiNve!within!12!months!of!commercial!launch!•  Risk!much!lower!by!iniNally!focusing!on!veterinary!devices!

that!are!in!lateEstage!development!•  Business!and!manufacturing!processes!easily!scalable!!!!!•  Products!proven!in!both!pets!&!humans!•  Extensive!pet!and!human!product!pipeline!•  InEclinic!treatments!grow!vet!pracNce!revenues!and!

accelerate!product!adopNon!•  Experienced!management!!•  Strong!intellectual!property!porvolio!

PetVivo™!Holdings,!Inc.!!OTCPINK:!PETV!

“Running!is!the!Life”!

12100!Singletree!Lane,!Suite!186!Eden!Prairie,!Minnesota!

Ph:!612E296E7305!jlai@petvivo.com!www.petvivo.com!

Appendix!A!!

Technology!!&!!

Manufacturing!!

Patented!BioCoacervaNon!!ProducNon!Process!

PrecipitaNon!of!Extracellular!Matrix!Components!(Collagen,!!!!!!ElasNn,!Heparin)!into!a!Coacervate!that!is!heat!processed!into!ThermoplasNc!Extracellular!Matrix!(ECM)!Biomaterial!

PrecipitaNon! CoacervaNon! Coacervate!

MasterGel!!Biomaterial!

*Enhanced!Extracellular!Matrix!Accumulation!in!Restenosis!of!Coronary!Arteries!After!Stent!Deployment,!IEM!Chung,!H.!K.!Gold,!S.!M.!Schwartz,!Y.!Ikari,!M.!A.!Reidy,!T.!N.!Wight!Journal(of(the(American(College(of(Cardiology(Vol!40,!No!12,!2002!!

ElasNn!

Glycosaminoglycans!

Natural!Precursor!ECM!!Formed!in!Coronary!Artery!!During!Stent!Restenosis*!

Matches!Natural!Precursor!Extracellular!Matrix!!! Osmium!Tetroxide!Stained!Samples!Show!Very!Similar!TEM!Micrographs!

!

CostEEfficient!Scalable!Manufacturing

•  Manufacturing!Process!FDA!Validated!for!Human!Clinical!Trial!ProducNon!

•  Manufacturing!Scaled!from!0.01!Kilograms!to!Several!Kilograms!in!Practice!E!Thousands!of!Syringes!

•  Very!Consistent!Lot!to!Lot!ProducNon!•  SingleEUse!Sterile!Bag!Processing!

Eliminates!Cleaning!Steps,!Reduces!Infrastructure!and!Increases!Capacity!

ThermoplasNc!ProperNes:!Simplified!Manufacturing;!Many!ApplicaNons Figure 1A

Coated!Catheter!

Molded!Gra{!

Melted!MasterGel!

Bener!Implant!Material:!Why?!!•  Isolated!Purified!Components!

o  Source!Tissues!Purified!to!Soluble!Component!Form!!o Memory!of!Source!Tissue!Type!Removed!!

•  Precludes!Wrong!Tissue!Response!e.g.,!Cadaveric!Tissue!!o No!Inflammatory!or!Foreign!Body!Response!!

•  Comprised!of!Collagen,!ElasNn!&!Heparin!o  Same!Components!As!Natural!Extracellular!Matrix!

•  Components!SelfEAssemble!=!BiocoacervaNon!o  Forms!Insoluble!Matrix!–!Slippery,!Wet,!Permeable,!Durable!&!Resilient!o  Mimics!Natural!Precursor!Scaffold!in!ComposiNon,!Structure!&!HydraNon!o  Promotes!NeovascularizaNon!&!is!NonEClo~ng!o  Facilitates!Cellular!IntegraNon!&!RegeneraNon!of!FuncNonal!Tissue!

•  Flexible!&!Adjustable!Biomaterial!Plavorm!!o  Modifying!ComposiNon!&!Components!Adjusts!Material!CharacterisNcs!!

Appendix!B!!

Human!TherapeuNcs!

!Leading!Human!Devices!

!!!SynovoLife™!

ORTHOPEDIC!JOINT!TREATMENTS!

!!!!SPINAL!DISC!TREATMENT&!!!!DiskLife™!! CARDIOVASCULAR!DISEASE!TREATMENTS!

!UroLife™!

TREATMENT!FOR!STRESS!URINARY!INCONTINENCE!

CosmetaLife®!(Injected!Dermal!Filler)!

100 um

Par0cles&in&Saline&Inverted&Microscope!

•  $1.3B!WW!Dermal!Filler!Market!

•  Growing!Market!10E15%!CAGR!

•  Successful!150!PaNent!Pivotal!Clinical!Trial!o  Met!FDA!Primary!Efficacy!Goal!!o  No!Different!Than!Restylane!!o  SplitEFace!Nasolabial!Fold!

CorrecNon!o  Next!Step:!PMA!Submission!

Pivotal!Clinical!Trial!Results:!!PaNents!Preferred!CosmetaLife™

CosmetaLife!dermal!filler!injected!into!one!side!and!Restylane!(Control)!injected!into!other!side!of!each!face.!Blinded!Subjects!scored!each!nasoElabial!fold!using!the!Global!AestheNc!Improvement!Scale!and!preferred!GelEDel’s!product!at!all!Nme!points.!

Details!found!at:!www.clinicaltrials.gov!NCT00414544!CosmetaLife

0!

20!

40!

60!

80!

100!

3EMos! 6EMos! 9EMos! 12Emos!

CosmetaLIfe!

Restylane!

Global&Aesthe0c&Improvement&Scale&–&Subject&Scored&IniNal!10!subjects!per!site!excluded.!Approximately!80!Subjects!

!!

Dermal!Filler!Market!&!Comps!•  $1.3B!WW!Dermal!Filler!Market1!

•  10E15%!CAGR!•  Our!comp!group!consists!of!other!dermal!filler!manufactures!and!distributors!o  Valeant/Nestle!May!2014!transacNon!($1.4B,!or!more!than!5.0x!sales)!!

o  Allergan!trades!at!over!7.0x!2014!E!sales!!

!!

1WW!Dermal!Filler!Market!is!an!average!of!the!following:!!!!Allergan:!2013!WW!Filler!Market!$1.3B,!CAGR!10%!(5/12/2014)!!!!Market!Research!Reports:!2013!WW!Filler!Market!$1.0B,!CAGR!15%!(6/17/14)!!

AddiNonal!Human!ParNcle!Devices!&!Markets!•  SynovoLife!–!Synovial!Joint!InjecNon!for!OsteoarthriNs!!!

•  6M!(7%)!in!US!SymptomaNc!Knee!OsteoarthriNs!between!age!50!to!84!years(1)!•  No!EffecNve!ReparaNve!Treatment;!Symptom!Treatment!or!Joint!Replacement!

•  CosmetaLife!–!Lip!Dermal!Filler!•  Extension!of!Dermal!Filler!With!An!IndicaNon!Specifically!For!Lip!Plumping!•  Current!Lip!Treatments!Either!Cause!Scarring!or!Dissipate!!

•  DiscLife!–!Spinal!Disc!Repair!!!•  More!Than!10%!of!US!Adults!Have!Chronic!Low!Back!Pain(2)!•  InjecNon!of!ParNcles!Into!Spinal!Disc!To!Expand/Repair!Disc!&!Relieve!Pain!!

•  UroLife!–!Female!Urinary!InconNnence!!•  ParNcles!Injected!Into!The!Bladder!Wall!Around!the!Urinary!Sphincter!to!Provide!

RegeneraNve!Tissue!Bulking!to!Stop!Urinary!Leakage!•  Current!Therapies!of!Limited!EffecNveness,!O{en!Require!Daily!MedicaNons!•  18.7%!of!Adult!Women!Affected!by!Urinary!InconNnence(3)!!

(1)!Losina!E,!Walensky!RP,!Reichmann!WM,!Holt!HL,!Gerlovin!H,!Solomon!DH,!et!al.!Impact!of!Obesity!and!Knee!OsteoarthriNs!on!1Morbidity!!!and!Mortality!in!Older!Americans.!Ann!Intern!Med.!2011;154:217E226.!!(2)!Freburger,!Janet!K.,!et!al.!"The!rising!prevalence!of!chronic!low!back!pain."!Archives!of!Internal!Medicine!169.3!(2009):!251E258.!(3)!Ebbesen,!Marit!H.,!et!al.!"Prevalence,!incidence!and!remission!of!urinary!inconNnence!in!women:!longitudinal!data!from!the!1Norwegian!HUNT!study!(EPINCONT)."!BMC!urology!13.1!(2013):!27.!

Ovine!TesNng!(n=12)!Toxicology!Comparison!Study!to!ePTFE!

Cardiovascular!Disease!Treatments!

VasoShunt!–!Arteriovenous!(AV)!Shunt!!!

!Cardiovascular!Devices!&!Markets!•  VasoShunt!–!Arteriovenous!(AV)!Shunt!

o  Annually!≈250,000!US!Dialysis!PaNents!Require!Vascular!Access!(US!Renal!Data!System)!

o  Over!50%!of!NaNve!&!ePTFE!Shunts!Fail!Within!1!year(1)!

•  VasoShunt!–!Temporary!Vascular!Shunt!for!Limb!Salvage!o  Treatment!of!Vascular!Injuries!in!Military!Theatre!&!Trauma!Se~ngs!o  No!Current!Temporary!Shunts!Have!NonEClo~ng!Feature!of!VasoShunt!

•  Peripheral!Vascular!Gra{!!o  WW!Market!Growing!From!$6.6B!in!2014!to!$8.4B!in!2018!–!CAGR!of!6.3%!(BCC!Research)!o  No!Peripheral!Vascular!Gra{s!with!NonEclo~ng!Features!of!VasoGra{!Available!!

•  Coronary!Artery!Bypass!Gra{!o  400,000!CABG!Procedures!Annually!In!US!(American!Heart!AssociaNon)!o  No!OffETheEShelf!Small!Diameter!Gra{s!Currently!Available!!

(1)Akoh!JA.!ProstheNc!AV!!Gra{s!for!!Hemodialysis.!J!Vasc!Access.!2009!JulESep;10(3):137E47.!Review.!PubMed!PMID:!19670164.!

VasoGra{!&!VasoShunt!–!Biomaterial!Conduit!!!!NonEClo~ng!ArNficial!Blood!Vessel

•  $5.7!M!in!NIH!Grant!Funding!•  Successful!180EDay!Swine!Studies!•  Successful!Pilot!ProducNon!•  Any!Type!of!Vascular!Gra{!or!Shunt!!•  Bener!Than!Gold!Standard!ePTFE!Gra{s!•  NonEClo~ng!ProperNes!

o  Devices!&!Device!CoaNngs!o  Improve!Any!Blood!ContacNng!Device!o  Stents,!Gra{s,!Catheters,!etc.!o  Allows!Small!Diameter!Gra{s!

•  Inherent!Drug!Delivery!Capability!!

CaroNd!artery! VasoShunt!

2!wk!implantaNon!(ovine)!

VasoShunt!

End!to!side!anastomosis!with!12!cm!long!VasoE!!!Gra{!shunNng!caroNd!to!jugular!in!sheep!(n=6)!

!Shunt!–!tube!of!biomaterial VasoShunt:!U.S.!Dept.!of!Defense!Porcine!Clo~ng!Study!•  Length!was!5!mm!i.d.!and!5E6!cm!long!(wall!thickness!matches!natural!

blood!vessel)!•  Able!to!shunt!severed!iliac!artery!for!4–5!hours!without!clo~ng!

(hemocompaNble)!!•  3.8!mm!ID!small!diameter!gra{s!patent!for!over!6!months!in!porcine!

femoral!artery!

Conclusion:!VasoShunt!shows!great!promise!for!short!term!circulatory!reconnecNon!of!severed!vessels!in!military!trauma!applicaNons!

Biomaterial!is!hemocompatable!and!structurally!sound!!

VasoShunt!

NaNve!Artery!

iliac artery shunt!